Patents by Inventor David Elliott Spaner

David Elliott Spaner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6733748
    Abstract: Chronic lymphocytic leukemia (CLL) in a patient is treated by administering to the patient oxidatively stressed CLL cells. The CLL cells are oxidatively stressed extracorporeally, e.g. by subjection to oxygen/ozone mixtures, and preferably are simultaneously subjected to other stressors such as UV light. Preferably also, the CLL cells are autologous, and are contained in an aliquot of the patient's blood at the time of subjection to stressing.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: May 11, 2004
    Assignee: Vasogen Ireland Limited
    Inventor: David Elliott Spaner
  • Publication number: 20020090358
    Abstract: Chronic lymphocytic leukemia (CLL) in a patient is treated by administering to the patient oxidatively stressed CLL cells. The CLL cells are oxidatively stressed extracorporeally, e.g. by subjection to oxygen/ozone mixtures, and preferably are simultaneously subjected to other stressors such as UV light. Preferably also, the CLL cells are autologous, and are contained in an aliquot of the patient's blood at the time of subjection to stressing.
    Type: Application
    Filed: October 25, 2001
    Publication date: July 11, 2002
    Inventor: David Elliott Spaner
  • Publication number: 20010028879
    Abstract: The development of graft versus host disease in a mammalian patient undergoing cell transplantation therapy for treatment of a bone marrow mediated disease, is prevented or alleviated by subjecting at least the T-cells of the allogeneic cell transplantation composition, extracorporeally, to oxidative stress, in appropriate dosage amounts, such as bubbling a gaseous mixture of ozone and oxygen through a suspension of the T-cells. The process may also include irradiation of the cells with UV light, simultaneously with the application of the oxidative stress. The oxidative stress induces reduced inflammatory cytokine production and a reduced proliferative response in the T-cells.
    Type: Application
    Filed: May 14, 2001
    Publication date: October 11, 2001
    Inventor: David Elliott Spaner